AstraZeneca PLC AZN
$ 65.36
1.44%
Annual report 2023
added 12-14-2024
AstraZeneca PLC Balance Sheet 2011-2024 | AZN
Annual Balance Sheet AstraZeneca PLC
2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | 9.86 B | 10.5 B | 12.5 B | 12.2 B | 11.8 B | 8.83 B | 4.49 B | 1.18 B | 2.61 B | 1.76 B | ||
Long Term Debt |
- | - | - | 17.5 B | 15.7 B | 17.4 B | 15.6 B | 14.5 B | 14.1 B | 8.34 B | 8.52 B | 9.41 B | 7.34 B |
Long Term Debt Current |
271 M | 228 M | 233 M | 192 M | 188 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 30.8 B | 28.7 B | 30.3 B | 30.3 B | 30.6 B | 26.7 B | 21.6 B | 16.6 B | 15.7 B | 13.6 B |
Total Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
62 B | 59.4 B | 66.1 B | 51.1 B | 46.8 B | 46.6 B | 46.7 B | 45.9 B | 41.6 B | 38.9 B | 32.6 B | 29.6 B | 29.4 B |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | - | 5.3 B | 2.81 B | 5.68 B | 8.22 B | 8.14 B | 11.8 B | 13 B | 17 B | 18 B | 17.9 B |
Total Assets |
101 B | 96.5 B | 105 B | 66.7 B | 61.4 B | 60.7 B | 63.4 B | 62.5 B | 60.1 B | 58.6 B | 55.9 B | 53.5 B | 52.8 B |
Cash and Cash Equivalents |
5.84 B | 6.17 B | 6.33 B | 7.83 B | 5.37 B | 4.83 B | 3.32 B | 5.02 B | - | - | - | - | - |
Book Value |
39.2 B | 37.1 B | 39.3 B | 15.6 B | 14.6 B | 14 B | 16.6 B | 16.7 B | 18.5 B | 19.6 B | 23.3 B | 24 B | 23.5 B |
Total Shareholders Equity |
- | - | - | 15.6 B | 14.6 B | 14 B | 16.6 B | 16.7 B | 18.5 B | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet AstraZeneca PLC
2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | 754 M | - | 492 M | - | 489 M | - | 465 M | - | 487 M | - | 514 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 43.5 B | - | 35.7 B | - | 30.8 B | - | 28.1 B | - | 28.7 B | - | 30.8 B | - | 30.3 B | - | 29.9 B | - | 30.3 B | - | 34 B | - | 30.6 B | - | - | - | 26.7 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | 66.1 B | - | 57.9 B | - | 51.1 B | - | 46.3 B | - | 46.8 B | - | 46.8 B | - | 46.6 B | - | 47.1 B | - | 46.7 B | - | 49.7 B | - | 45.9 B | - | - | - | 41.5 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | - | - | 1.71 B | - | 5.34 B | - | 5.3 B | - | 1.91 B | - | 2.81 B | - | 3.26 B | - | 5.68 B | - | 5.88 B | - | 8.22 B | - | 6.93 B | - | 8.14 B | - | - | - | 11.8 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
- | - | - | - | 105 B | - | 73.6 B | - | 66.7 B | - | 59.9 B | - | 61.4 B | - | 61.9 B | - | 60.7 B | - | 61.3 B | - | 63.4 B | - | 65.1 B | - | 62.5 B | - | - | - | 60.1 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | - | - | - | 6.33 B | - | 15.6 B | - | 7.83 B | - | 5.67 B | - | 5.37 B | - | 5.43 B | - | 4.83 B | - | 2.98 B | - | 3.32 B | - | 5.24 B | - | 5.02 B | - | - | - | 6.24 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
- | - | - | - | 39.3 B | - | 15.7 B | - | 15.6 B | - | 13.7 B | - | 14.6 B | - | 15.1 B | - | 14 B | - | 14.3 B | - | 16.6 B | - | 15.4 B | - | 16.7 B | - | - | - | 18.5 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | - | - | - | 39.3 B | - | 15.7 B | - | 15.6 B | - | 13.7 B | - | 14.6 B | - | 15.1 B | - | 14 B | - | 14.3 B | - | 16.6 B | - | 15.4 B | - | 16.7 B | - | - | - | 18.5 B | - | - | - | 19.6 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency